Resveratrol in primary and secondary prevention of cardiovascular disease: A dietary and clinical perspective

Annals of the New York Academy of Sciences

Volumn 1290, Issue 1, 2013, Pages 37-51

  Tomé Carneiro, João ^a   Gonzálvez, Manuel ^b   Larrosa, Mar ^a   Yáñez Gascón, María J ^a   García Almagro, Francisco J ^b   Ruiz Ros, José A ^b   Tomás Barberán, Francisco A ^a   García Conesa, María T ^a   Espín, Juan Carlos ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Cardiovascular; Clinical trial; Grape; Nutraceutical; Polyphenol; Resveratrol

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ADIPONECTIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESVERATROL; SERUM AMYLOID A; STILVID; SUPEROXIDE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; ARTICLE; CARDIOVASCULAR DISEASE; CELL MIGRATION; CREATININE BLOOD LEVEL; DIETARY INTAKE; DRUG DISPOSITION; DYSLIPIDEMIA; EXERCISE; FOLLOW UP; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART PROTECTION; HUMAN; IN VITRO STUDY; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECONDARY PREVENTION; SMOKING CESSATION; TREATMENT DURATION; UPREGULATION;

EID: 84880366330     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12150     Document Type: Article

References (75)

1. Scalbert, A. & G. Williamson. 2000. Dietary intake and bioavailability of polyphenols. J. Nutr. 130: 2073S-2085S.
2. Vang, O. et al. 2011. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6: e19881.
3. Langcake, P. & R.J. Pryce. 1976. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant. Pathol. 9: 77-86.
4. Cantos, E., J.C. Espín & F.A. Tomás-Barberán. 2001. Postharvest induction modeling method using UV irradiation pulses for obtaining resveratrol-enriched table grapes: a new "functional" fruit? J. Agric. Food Chem. 49: 5052-5058.
5. Stervbo, U., O. Vang & C. Bonnesen. 2007. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem. 101: 449-457.
6. Sanders, M.A. & A.P. Majumdar. 2011. Colon cancer stem cells: implications in carcinogenesis. Front. Biosci. 16: 1651-1662.
7. Rimando, A.M. et al. 2004. Resveratrol, pterostilbene, and piceatanol in Vaccinium berries. J. Agric. Food Chem. 57: 4713-4719.
8. Tokusoglu, O., M.K. Unal & F. Yemis. 2005. Determination of the phytoalexin resveratrol (3, 5, 4′-trihydroxystilbene) in peanuts and pistachios by high-performance liquid chromatographic diode array (HPLC-DAD) and gas chromatography-mass Spectrometry (GC-MS). J. Agric. Food Chem. 53: 5003-5009.
9. Renaud, S. & M. de Lorgeril. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
10. Alfaras, I. et al. 2010. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J. Agric. Food Chem. 58: 4523-4528.
11. van de Wetering, K. et al. 2009. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol. 75: 876-885.
12. Juan, M.E., E. González-Pons & J.M. Planas. 2010. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr. 140: 489-495.
13. Azorín-Ortuño M. et al. 2011. Metabolites and tissue distribution of resveratrol in the pig. Mol. Nutr. Food Res. 55: 1154-1168.
14. Johnson, J.J. et al. 2011. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 55: 1169-1176.
15. Amiot, M.J. et al. 2013. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie. 95: 1233-1238.
16. Graham, I. et al. 2007. European guidelines on cardiovascular disease prevention in clinical practice. fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (Constituted by representatives of nine societies and by invited experts). Eur. Heart J. 28: 2375-2414.
17. Lloyd-Jones, D.M. et al. 2010. American Heart Association strategic planning task force and statistics committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association's strategic impact goal through 2020 and beyond. Circulation 121: 586-613.
18. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
19. Yu, P.B. & H.Y. Chung. 2006. The inflammatory process in ageing. Rev. Clin. Gerontol. 16: 179-187.
20. Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
21. Wu, J.M. & T.C. Hsieh. 2011. Resveratrol: a cardioprotective substance. Ann. N. Y. Acad. Sci. 1215: 16-21.
22. Wang, H. et al. 2012. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev. 17: 437-448.
23. Tomé-Carneiro, J. et al. 2013. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. In press.
24. Maxie, M.G. & W.F. Robinson. 2007. "Cardiovascular system." In Jubb, Kennedy and Palmer's Pathology of Domestic Animals. M.G. Maxie, Ed.: 1-103. Philadelphia: Elsevier Saunders.
25. Xiangdong, L. et al. 2011. Animal models for the atherosclerosis research: a review. Protein Cell 2: 189-201.
26. Robich, M.P. et al. 2010. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 122: S142-S149.
27. Robich, M.P. et al. 2011. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur. J. Pharmacol. 664: 45-53.
28. Robich, M.P. et al. 2012. Resveratrol preserves myocardial function and perfusion in remote nonischemic myocardium in a swine model of metabolic syndrome. J. Am. Coll. Surg. 215: 681-689.
29. Azorín-Ortuño, M. et al. 2012. A dietary resveratrol-rich grape extract prevents the developing of atherosclerotic lesions in the aorta of pigs fed an atherogenic diet. J. Agric. Food Chem. 60: 5609-5620.
30. Azorín-Ortuño, M. et al. 2012. Effects of long-term consumption of low doses of resveratrol on diet-induced mild hypercholesterolemia in pigs: a transcriptomic approach to disease prevention. J. Nutr. Biochem. 23: 829-837.
31. Brasnyó, P. et al. 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106: 383-389.
32. Fujitaka, K. et al. 2011. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr. Res. 31: 842-847.
33. Bhatt, J.K., S. Thomas & M.J. Nanjan. 2012. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 32: 537-541.
34. Magyar, K. et al. 2012. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50: 179-187.
35. Crandall, J.P. et al. 2012. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. A. Biol. Sci. Med. Sci. 67: 1307-1312.
36. Militaru, C. et al. 2013. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 29: 178-183.
37. Banegas, J.R. et al. 2011. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur. Heart J. 32: 2143-2152.
38. Agewall, S. 2011. The large clinical statin trials. Int. J. Cardiol. 150: 108-111.
39. Tomé-Carneiro, J. et al. 2012. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 56: 810-821.
40. Tomé-Carneiro, J. et al. 2012. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 110: 356-363.
41. Tomé-Carneiro, J. et al. 2013. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 27: 37-48.
42. Cantos, E., J.C. Espín & F.A. Tomás-Barberán. 2002. Postharvest stilbene-enrichment of red and white table grape varieties using UV-C irradiation pulses. J. Agric. Food Chem. 50: 6322-6329.
43. Ehara, S. et al. 2001. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103: 1955-1960.
44. Contois, J.H., G.R. Warnick & A.D. Sniderman. 2011. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J. Clin. Lipidol. 5: 264-272.
45. Grundy, S.M. 2002. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106: 2526-2529.
46. Genest, J. 2003. Recommendations for the management of dyslipidemias and the prevention of cardiovascular disease: summary of the 2003 update. JAMC 169: 921-924.
47. Sniderman, A.D. et al. 2011. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes 4: 337-345.
48. Weil, B.R. et al. 2011. Relation of C-reactive protein to endothelial fibrinolytic function in healthy adults. Am. J. Cardiol. 108: 1675-1679.
49. Reiner, Z. et al. 2011. European association for cardiovascular prevention and rehabilitation. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32: 1769-1818.
50. Benagiano, M. et al. 2003. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 100: 6658-6663.
51. Lin, Z. et al. 2005. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ. Res. 96: e48-e57.
52. Libby, P. & F. Crea. 2010. Clinical implications of inflammation for cardiovascular primary prevention. Eur. Heart J. 31: 777-783.
53. Smith, S.C., Jr et al. 2011. World heart federation and the preventive cardiovascular nurses association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the american heart association and american college of cardiology foundation endorsed by the world heart federation and the preventive cardiovascular nurses association. J. Am. Coll. Cardiol. 58: 2432-2446.
54. World Health Organization. 2007. Prevention of Cardiovascular Disease. Guidelines for Assessment and Management of Cardiovascular Risk. Geneva: WHO Press.
55. Pauwels, E.K. 2011. The protective effect of the mediterranean diet: focus on cancer and cardiovascular risk. Med. Princ. Pract. 20: 103-111.
56. Maruyoshi, H. et al. 2004. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb. Haem. 91: 1026-1030.
57. Chan, K.C. et al. 2008. Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level. Clin. Cardiol. 31: 253-258.
58. Kohler, H.P. & P.J. Grant. 2000. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342: 1792-1801.
59. Belalcazar, L.M. et al. 2011. Look Action for Health in Diabetes Research Group. Look action for health in diabetes research group. metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look ahead study. Arterioscler. Thromb. Vasc. Biol. 31: 1689-1695.
60. Mertens, I. et al. 2005. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. Thromb. Haemost. 94: 1190-1195.
61. Picard, F. et al. 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
62. Subauste, A.R. & C.F. Burant. 2007. Role of FoxO1 in FFA-induced oxidative stress in adipocytes. Am. J. Physiol. Endocrinol. Metab. 293: E159-164.
63. Kazemian, P. et al. 2012. The use of Ω-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes. Cardiovasc. Drugs Ther. 26: 311-320.
64. Yoshino, J. et al. 2012. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 16: 658-664.
65. Poulsen, M.M. et al. 2012. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 62: 1186-1195.
66. Willrich, M.A., M.H. Hirata & R.D. Hirata. 2009. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 10: 1017-1024.
67. Chow, H.H. et al. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila) 3: 1168-1175.
68. Planas, J.M. et al. 2012. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch. Biochem. Biophys. 527: 67-73.
69. The AIM-HIGH Investigators. 2011. The role of niacin in raising HDL-C to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated LDL-c AIM-HIGH: rationale and study design. Am. Heart J. 161: 471-477.
70. Nicholls, S.J. 2012. The AIM-HIGH (Atherothrombosis intervention in metabolic syndrome with low HDL/High triglycerides: impact on global health outcomes) trial: to believe or not to believe? J. Am. Coll. Cardiol. 59: 2065-2067.
71. Gouni-Berthold, I. & H.K. Berthold. 2013. The role of niacin in lipid-lowering treatment: are we aiming too high? Curr. Pharm. Des. 19: 3094-3106.
72. Berglund, L. et al. 2012. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 97: 2969-2989.
73. Chapman, M.J. et al. 2011. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32: 1345-1361.
74. Di Chiara, A. & D. Vanuzzo. 2009. Does surveillance impact on cardiovascular prevention? Eur. Heart J. 30: 1027-1029.
75. Tome-Carneiro, J. et al. 2013. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. doi:org/10.1016/j.phrs.2013.03.011.